What disease is Lisocabtagene maraleucel (Beryanzi) used to treat?

Lisocabtagene maraleucel (trade name: Beryanzi) is an innovative medicine that is used to treat certain types of blood cancers, especially adults with refractory or relapsed large B cell lymphoma (DLBCL). The drug represents an important milestone in CAR-T cell therapy and offers a new and promising treatment option for some cancer patients.

DLBCL is a subtype of non-Hodgkin lymphoma (Non-Hodgkin lymphoma, NHL) that originates from B cells in the lymphatic system. Lymphoma is a type of leukemia or lymphoma that often causes malignant cells in the lymphatic system to proliferate and form tumors. DLBCLUsually manifests as symptoms such as swollen lymph nodes, fever, night sweats, fatigue, and weight loss. While DLBCLcan be treated in some cases with traditional chemotherapy, radiation, and immunotherapy, for some patients these approaches may fail, or the disease may return. This is the value of Lisocabtagene maraleucel.

Lisocabtagene maraleucelis a CAR-T cell therapy that works by improving the patient's own immune system to fight cancer cells. CAR-T stands for"Chimeric Antigen ReceptorTcells"（Chimeric Antigen Receptor T-cell), an experimental treatment that has achieved remarkable success in treating some leukemias and lymphomas. Lisocabtagene maraleucel owes its efficacy to its unique working principle.

Lisocabtagene maraleucelis a treatmentDLBCLIt is an innovative drug that represents the development direction of CAR-T cell therapy. It offers a new treatment option for patients who have failed or are resistant to traditional treatments, but patients and doctors must weigh its potential benefits and risks to make the best treatment decisions. At the same time, with the progress of scientific research, CAR-T cell therapy is expected to play a more important role in future cancer treatment.